Nkarta
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 150
- Market Cap
- $379.6M
- Website
- http://www.nkartatx.com
- Introduction
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Nkarta Appoints Immunology Expert Shawn Rose as Chief Medical Officer to Lead Autoimmune NK Cell Therapy Development
Nkarta has appointed Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of R&D, effective June 23, 2025, replacing David R. Shook who is returning to oncology.
Lupus Nephritis Market Expected to Grow as Novel Therapies Enter Clinical Trials
The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.
Nkarta's NKX019 Cell Therapy Trial Opens Enrollment for ANCA-Associated Vasculitis
Nkarta has initiated enrollment for the Ntrust-2 clinical trial to evaluate NKX019 cell therapy in patients with ANCA-associated vasculitis (AAV) and other autoimmune disorders.
NK Cell Therapy Pipeline Shows Promise with Over 160 Therapies in Development
The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.
Nkarta Prioritizes NKX019 for Autoimmune Diseases, Forgoes Lymphoma Development
Nkarta has dosed the first patient in both the Ntrust-1 trial (lupus nephritis) and the investigator-sponsored trial (systemic lupus erythematosus) of NKX019, with enrollment ongoing.